Overactive Bladder Treatment Market

Executive Summary

Overactive Bladder Treatment Market was valued at US $4,434.51 million in 2021 and is projected to grow at 3.23% CAGR over the forecast period to reach US $5,365.08 million by 2027. Overactive Bladder Treatment Market represented US $272.83 million opportunity over 2019-2021 and estimated to create US $930.57 million opportunity in 2027 over 2021.

Overactive Bladder Treatment from Consainsights analyses the Overactive Bladder Treatment Market in the Life Sciences industry over the forecast period to 2027.

Overactive Bladder Treatment research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Overactive Bladder Treatment segmentation includes Pharmacotherapy, Disease and Geography.

Based on the Pharmacotherapy, the Overactive Bladder Treatment analysis covers Anticholinergics, Mirabegron, Botox, Neurostimulation, Intravesical Instillation.

In Pharmacotherapy segment, Anticholinergics segment has highest cagr growth of 2.86%.

Based on the Disease, the Overactive Bladder Treatment analysis covers Idiopathic Overactive Bladder, Neurogenic Overactive Bladder.

In Disease segment, Idiopathic Overactive Bladder segment has highest cagr growth of 2.86%.

Based on the region, the Overactive Bladder Treatment analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Astellas Pharma Inc., Pfizer, Inc., Teva Pharmaceutical Industries Limited, Allergan, Plc., Mylan N.V., Endo International Plc, Hisamitsu Pharmaceutical Co., Inc., Sanofi, Aurobindo Pharma Limited, Johnson & Johnson, Intas Pharmaceuticals Ltd., Apotex Inc., Macleods Pharmaceuticals Ltd., Medtronic Plc, Cogentix Medical, Inc. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Pharmacotherapy

Introduction

In 2021, Anticholinergics segment has the highest revenue of US $1,783.77 million and is expected to grow at CAGR of 2.86% by 2027 Anticholinergics segment has highest cagr growth of 2.86%.

Anticholinergics

Anticholinergics segment was valued at US $1,674.03 million in 2019 and is projected to grow at 2.86% CAGR over the forecast period to reach US $2,158.09 million by 2027. Anticholinergics segment represented US $109.75 million opportunity over 2019-2021 and estimated to create US $374.32 million opportunity in 2027 over 2021.

Mirabegron

Mirabegron segment was valued at US $1,063.65 million in 2019 and is projected to grow at 2.86% CAGR over the forecast period to reach US $1,371.21 million by 2027. Mirabegron segment represented US $69.73 million opportunity over 2019-2021 and estimated to create US $237.84 million opportunity in 2027 over 2021.

Botox

Botox segment was valued at US $822.00 million in 2019 and is projected to grow at 2.86% CAGR over the forecast period to reach US $1,059.69 million by 2027. Botox segment represented US $53.89 million opportunity over 2019-2021 and estimated to create US $183.80 million opportunity in 2027 over 2021.

Neurostimulation

Neurostimulation segment was valued at US $394.22 million in 2019 and is projected to grow at 2.86% CAGR over the forecast period to reach US $508.21 million by 2027. Neurostimulation segment represented US $25.84 million opportunity over 2019-2021 and estimated to create US $88.15 million opportunity in 2027 over 2021.

Intravesical Instillation

Intravesical Instillation segment was valued at US $207.79 million in 2019 and is projected to grow at 2.86% CAGR over the forecast period to reach US $267.87 million by 2027. Intravesical Instillation segment represented US $13.62 million opportunity over 2019-2021 and estimated to create US $46.46 million opportunity in 2027 over 2021.

Disease

Introduction

In 2021, Idiopathic Overactive Bladder segment has the highest revenue of US $3,551.84 million and is expected to grow at CAGR of 2.86% by 2027 Idiopathic Overactive Bladder segment has highest cagr growth of 2.86%.

Idiopathic Overactive Bladder

Idiopathic Overactive Bladder segment was valued at US $3,333.32 million in 2019 and is projected to grow at 2.86% CAGR over the forecast period to reach US $4,297.19 million by 2027. Idiopathic Overactive Bladder segment represented US $218.52 million opportunity over 2019-2021 and estimated to create US $745.35 million opportunity in 2027 over 2021.

Neurogenic Overactive Bladder

Neurogenic Overactive Bladder segment was valued at US $828.36 million in 2019 and is projected to grow at 2.86% CAGR over the forecast period to reach US $1,067.89 million by 2027. Neurogenic Overactive Bladder segment represented US $54.31 million opportunity over 2019-2021 and estimated to create US $185.23 million opportunity in 2027 over 2021.